share_log

Clene | 10-K: FY2023 Annual Report

Clene | 10-K: FY2023 Annual Report

Clene | 10-K：2023財年年報
美股SEC公告 ·  2024/03/13 19:53

Moomoo AI 已提取核心訊息

Clene Inc., a clinical-stage pharmaceutical company, reported its annual financial results, highlighting a 38% increase in total revenue from $473,000 in 2022 to $654,000 in 2023. This growth was driven by a 51% rise in product revenue and an 8% increase in royalty revenue. Despite this, the company experienced a 16% decrease in operating expenses, primarily due to reduced research and development costs, which fell from $31.92 million to $26.655 million. General and administrative expenses also decreased by 15%. However, Clene Inc. reported a net loss of $49.504 million, a 65% increase from the previous year's $29.918 million loss. The company has not yet achieved profitability and has no drugs approved for commercial sale. Clene Inc. continues to focus on developing its novel clean-surfaced nanotechnology (CSN®) therapeutics, with multiple drug assets in development and clinical trials, primarily for neurology applications. The company's future plans include initiating an international Phase 3 study of CNM-Au8 30 mg, RESTORE-ALS, in the second half of 2024, contingent upon funding, and further engagement with the FDA to support potential approval of their drug candidates.
Clene Inc., a clinical-stage pharmaceutical company, reported its annual financial results, highlighting a 38% increase in total revenue from $473,000 in 2022 to $654,000 in 2023. This growth was driven by a 51% rise in product revenue and an 8% increase in royalty revenue. Despite this, the company experienced a 16% decrease in operating expenses, primarily due to reduced research and development costs, which fell from $31.92 million to $26.655 million. General and administrative expenses also decreased by 15%. However, Clene Inc. reported a net loss of $49.504 million, a 65% increase from the previous year's $29.918 million loss. The company has not yet achieved profitability and has no drugs approved for commercial sale. Clene Inc. continues to focus on developing its novel clean-surfaced nanotechnology (CSN®) therapeutics, with multiple drug assets in development and clinical trials, primarily for neurology applications. The company's future plans include initiating an international Phase 3 study of CNM-Au8 30 mg, RESTORE-ALS, in the second half of 2024, contingent upon funding, and further engagement with the FDA to support potential approval of their drug candidates.
臨床階段藥品公司Clene報告稱，其年度財務業績表現良好，總營業收入自2022年的473,000美元增長38%至2023年的654,000美元。這種增長的推動力來自產品銷售收入增長51%和版稅收入增長8%。儘管如此，由於研發成本降低，從3192萬美元下降到2665.5萬美元，公司的營業費用下降了16%。總部和行政費用也減少了15%。然而，Clene報告淨虧損4950.4萬美元，比前一年的2991.8萬美元虧損增加了65%。該公司尚未實現盈利，並且沒有獲得商業銷售批准的藥品。Clene繼續專注於開發其具有創新性的納米技術(CSN®)治療方案，擁有多種藥品資產正在開發和進行臨床試驗，主要用於神經學應用。該公司未來計劃包括在2024年下半年開始進行CNm-Au8 30毫克的國際3期研究RESTORE-ALS（如獲得資金支持），並進一步與FDA合作支持其藥品候選人的潛在批准。
臨床階段藥品公司Clene報告稱，其年度財務業績表現良好，總營業收入自2022年的473,000美元增長38%至2023年的654,000美元。這種增長的推動力來自產品銷售收入增長51%和版稅收入增長8%。儘管如此，由於研發成本降低，從3192萬美元下降到2665.5萬美元，公司的營業費用下降了16%。總部和行政費用也減少了15%。然而，Clene報告淨虧損4950.4萬美元，比前一年的2991.8萬美元虧損增加了65%。該公司尚未實現盈利，並且沒有獲得商業銷售批准的藥品。Clene繼續專注於開發其具有創新性的納米技術(CSN®)治療方案，擁有多種藥品資產正在開發和進行臨床試驗，主要用於神經學應用。該公司未來計劃包括在2024年下半年開始進行CNm-Au8 30毫克的國際3期研究RESTORE-ALS（如獲得資金支持），並進一步與FDA合作支持其藥品候選人的潛在批准。
有用
沒用

該公告為獨立文件：

獨立文件1  查看翻譯

獨立文件2  查看翻譯

獨立文件3  查看翻譯

獨立文件4  查看翻譯

獨立文件5  查看翻譯

獨立文件6  查看翻譯

獨立文件7  查看翻譯

獨立文件8  查看翻譯

獨立文件9  查看翻譯

声明：本內容僅用作提供資訊及教育之目的，不構成對任何特定投資或投資策略的推薦或認可。 更多信息
    相關股票 相關股票
    代碼 迷你走勢 最新價
    Agape ATP
    ATPC
    -- 1.170
    Seneca Foods-B
    SENEB
    -- 90.990
    榮業食品
    WYHG
    -- 9.490
    CIMG
    IMG
    -- 0.529
    BioHarvest Sciences
    BHST
    -- 6.555
    解鎖完整榜單
    重估中國資產
    繼中國開創性的DeepSeek技術推出之後，華爾街大行重估對中國市場的投資前景。
    熱門討論
    FOMC維持利率但不確定性高企：美股後市走向如何？
    🎙️討論 1. 美聯儲強調政策路徑存在「高度不確定性」，你更關注利率預期變化還是經濟數據對市場的短期影響？ 2. 若核心通脹維持高位，哪類板塊更具交易機會——防禦型股票還是科技成長股？ 展开
    聯邦公開市場委員會新聞發佈會，2025年3月19日